Literature DB >> 34844077

Cerebrospinal fluid dynamics and discordant amyloid biomarkers.

Jonathan Graff-Radford1, David T Jones2, Heather J Wiste3, Petrice M Cogswell4, Stephen D Weigand3, Val Lowe4, Benjamin D Elder5, Prashanthi Vemuri4, Argonde Van Harten2, Michelle M Mielke3, David S Knopman2, Neill R Graff-Radford6, Ronald C Petersen2, Clifford R Jack4, Jeffrey L Gunter7.   

Abstract

Do MRI-based metrics of a CSF-dynamics disorder, disproportionately enlarged subarachnoid-space hydrocephalus (DESH), correlate with discordant amyloid biomarkers (low CSF β-amyloid 1-42, normal Aβ-PET scan)? Individuals ≥50 years from the Mayo Clinic Study of Aging, with MRI, 11C-Pittsburgh compound B (Aβ) PET scans, and CSF phosphorylated-tau protein and Aβ42, were categorized into 4 groups: normal and/or abnormal by CSF β-amyloid 1-42 and Aβ amyloid PET. Within groups, we noted MRI patterns of CSF-dynamics disorders and Aβ-PET accumulation-change rate. One-hundred participants (21%) in the abnormal-CSF and/or normal-PET group had highest DESH-pattern scores and lowest CSF-phosphorylated-tau levels. Among normal amyloid-PET individuals, a 1-unit DESH-pattern score increase correlated with 30%-greater odds of abnormal amyloid CSF after age, and sex adjustment. Mean rate over time of amyloid-PET accumulation in abnormal-CSF and/or normal-PET individuals approximated individuals with normal amyloid values. Adjusting for phosphorylated-tau, abnormal CSF-amyloid and/or normal amyloid-PET individuals had higher mean amyloid-PET accumulation rates than normal individuals. CSF dynamics disorders confound β-amyloid and phosphorylated-tau CSF-biomarker interpretation.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Alzheimer's disease; Amyloid PET accumulation; Biomarkers; Disproportionately enlarged subarachnoid-space hydrocephalus (DESH); Mayo Clinic Study of Aging (MCSA); Normal-pressure hydrocephalus

Mesh:

Substances:

Year:  2021        PMID: 34844077      PMCID: PMC8758540          DOI: 10.1016/j.neurobiolaging.2021.10.017

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  31 in total

1.  Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus.

Authors:  Neill R Graff-Radford
Journal:  Neurology       Date:  2014-10-21       Impact factor: 9.910

2.  Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus.

Authors:  Adila Elobeid; Katarina Laurell; Kristina Giuliana Cesarini; Irina Alafuzoff
Journal:  J Neuropathol Exp Neurol       Date:  2015-05       Impact factor: 3.685

Review 3.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

4.  Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers.

Authors:  Anna Jeppsson; Henrik Zetterberg; Kaj Blennow; Carsten Wikkelsø
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

5.  CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.

Authors:  A Agren-Wilsson; A Lekman; W Sjöberg; L Rosengren; K Blennow; A T Bergenheim; J Malm
Journal:  Acta Neurol Scand       Date:  2007-11       Impact factor: 3.209

6.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

7.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

8.  CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.

Authors:  Argonde C Van Harten; Heather J Wiste; Stephen D Weigand; Michelle M Mielke; Walter K Kremers; Udo Eichenlaub; Richard Batrla-Utermann; Roy B Dyer; Alicia Algeciras-Schimnich; David S Knopman; Clifford R Jack; Ronald C Petersen
Journal:  Neurology       Date:  2020-06-26       Impact factor: 9.910

9.  P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.

Authors:  Michelle R Campbell; Susan Ashrafzadeh-Kian; Ronald C Petersen; Michelle M Mielke; Jeremy A Syrjanen; Argonde C van Harten; Val J Lowe; Clifford R Jack; Joshua A Bornhorst; Alicia Algeciras-Schimnich
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-18

Review 10.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

View more
  1 in total

1.  Ventricular volume in relation to lumbar CSF levels of amyloid-β 1-42, tau and phosphorylated tau in iNPH, is there a dilution effect?

Authors:  Simon Lidén; Dan Farahmand; Katarina Laurell
Journal:  Fluids Barriers CNS       Date:  2022-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.